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Introduction
Multiple myeloma (MM) is a neoplasia of plasma cells (PCs),
hallmarked by tumor cell tropism for the bone marrow (BM) and
production of monoclonal immunoglobulin (Ig) detectable in
serum and/or urine. Although MM is the 2nd most commonly
diagnosed hematologic malignancy in the Western world, it is
often viewed inaccurately as a rare disease because the short
survival (compared to many other hematologic neoplasias) and
uniformly fatal outcome of patients markedly decreases the
prevalence of MM in the population. MM incidence is higher in
men than women and is higher in African and lower in Asian
populations, relative to Caucasians. Despite extensive epidemi-
ological studies, specific modifiable risk factors for MM have not
yet been conclusively identified.
Multistep temporal evolution of MM
MM pathophysiology encompasses a multistage evolution
through monoclonal gammopathy of undetermined signifi-
cance (MGUS), smoldering (asymptomatic) MM, symptomatic
(intramedullary) MM, and extramedullary MM/plasma cell
leukemia (PCL). MGUS, an asymptomatic premalignant condi-
tion present in 1% and 3% of individuals age >50 and >70,
respectively, can stochastically progress to MM or related plas-
ma cell dyscrasias, with ?1% annual risk and 25% cumulative
probability of progression over 20 years (Kyle et al., 2002).
Smoldering MM, an intermediate entity between MGUS and
active MM, lacks MM-related symptoms, but often progresses,
after variable periods of time, to overt symptomatic MM. The
latter can be manifested clinically by anemia, lytic bone lesions
(predominantly in axial skeleton) and diffuse osteoporosis,
hypercalcemia, renal dysfunction (due to monoclonal Ig depo-
sition), and increased risk for infection. In advanced disease,
malignant PCs can form extramedullary lesions (e.g., soft tis-
sue plasmacytomas) and be detected in the circulation as PCL.
Genetic basis of MM
An accumulating compendium of data acquired with diverse
techniques (reviewed in Fonseca et al., 2004) reveals marked
interpatient heterogeneity in the genetic background of MM
cells. Unlike other hematologic malignancies (e.g., chronic
myelogenous leukemia with Philadelphia chromosome), MM
lacks pathognomonic genetic lesion(s) that could account,
either per se or in concerted fashion, for all cases of this dis-
ease. MM cells can harbor (1) hyperdiploid karyotypes with
infrequent translocations (<30%) or other structural chromoso-
mal abnormalities, or (2) nonhyperdiploid (e.g., hypodiploid,
hypotetraploid, or pseudodiploid) karyotypes with high preva-
lence of translocations (>85%) of Ig gene. These translocations
juxtapose potent Ig gene enhancers next to highly diverse, but
nonrandom, oncogene-harboring, partner loci: 11q13 (cyclin
D1), 4p16 (FGFR3 and MMSET), 16q23 (c-maf), 6p21 (cyclin
D3), and 20q11 (maf-B) account for ?40% of cases harboring
Ig translocations.The rest involves a multitude of other, less fre-
quent, partner loci (Avet-Loiseau et al., 2002; Fonseca et al.,
2004). A recent hypothesis proposes that at least one of cyclins
D1, D2, and/or D3 is overexpressed in MM, either through direct
(11q13-cyclin D1 and 6p21-cyclin D3) or indirect (4p16, 16q23,
other cyclin D2) effect of primary Ig translocations or through
yet undefined mechanism(s) in hyperdiploid MM cells
(Hideshima et al., 2004). Upregulation of cyclin D genes is pro-
posed to render PCs more responsive to proliferative stimuli,
e.g., BM-derived cytokines, resulting in selective expansion of a
PC population further susceptible to additional genetic events
(e.g., trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21;
loss of 13q14, often present in premalignant MGUS; and
p16INK4a methylation/inactivation) that can lead to MGUS/MM
(Avet-Loiseau et al., 2002; Fonseca et al., 2004; Rasillo et al.,
2003).
To date, no known transcriptional (Davies et al., 2003; Zhan
et al., 2003), cytogenetic (Fonseca et al., 2004), or mutational
markers can clearly distinguish MGUS from MM. However, a
multitude of adjunct genetic changes, which are absent or rare in
MGUS, are increasingly prevalent in aggressive intramedullary
MM or extramedullary MM and conceivably contribute to further
progression of MM to its more aggressive stages, including sec-
ondary chromosomal translocations (e.g., involving c-myc),
mutually exclusive activating mutations of K- or N-Ras (or FGF-
R3 in cases of t[4;14] translocation), mutations and/or monoallel-
ic p53 deletion, Rb or p18INK4c inactivation, or PTEN
deletions/inactivating mutations (Bezieau et al., 2002; Chesi et
al., 2002; Fonseca et al., 2004; Shou et al., 2000). Univariate
analyses of clinical outcome suggest improved survival after
high-dose chemotherapy for patients with t(11;14)(q13;q32) or
adverse prognosis in chemotherapy-treated patients harboring
t(4;14)(p16.3;q32), t(14;16)(q32;q23), or chromosome 13 dele-
tion(s) (Fonseca et al., 2004; Moreau et al., 2002; Shaughnessy
et al., 2003). However, the biological significance of individual
cytogenetic abnormalities remains elusive, e.g., due to different
detection sensitivity of various cytogenetic techniques and con-
founding effects of concomitant presence of multiple genetic
abnormalities and their evolving complexity during the course of
the disease. The biological behavior of MM cells is determined
by the composite effect of coexisting genetic lesions rather than
as exclusive repercussion of any individual one. To address this
limitation of univariate prognostic analyses, the multivariate
capabilities of cDNA or oligonucleotide microarrays have been
recruited to identify genes differentially expressed in malignant
PCs versus normal counterparts or transcriptional signatures
associated with MM patient subgroups which partially overlap
with proposed cytogenetic-based classifications (Davies et al.,
2003; Hideshima et al., 2004; Zhan et al., 2002). More studies
will be needed to identify the most biologically relevant of these
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transcripts and decipher the clinical applicability of these pro-
posed classifications, especially in the face of ongoing changes
in the therapeutic management of MM.
The role of BM microenvironment in MM pathophysiology
The biological and clinical behavior of MM cells is not exclusive-
ly determined by their genetic background. It is also influenced
by their intricate bidirectional relationship with their local bone
microenvironment: MM cells perturb normal skeletal homeosta-
sis, causing debilitating osteolytic lesions, while the BM milieu
provides MM cells with a multifaceted network of protective
effects against proapoptotic insults.
Under physiological conditions, the skeleton undergoes
ongoing structural remodeling to optimize its stress-bearing
capacity, via precisely coordinated cycles of osteoclast-mediat-
ed resorption of old bone and subsequent compensatory bone
formation by osteoblasts. In MM, however, these 2 opposing
processes are uncoupled, due to (1) concomitant upregulation
of multiple positive regulators of osteoclast formation and func-
tion, and (2) suppression of negative regulators of osteoclasto-
genesis and/or positive regulators of bone formation (Ashcroft
et al., 2003). RANK (receptor activator of nuclear factor-κB [NF-
κB]), a TNF receptor superfamily member expressed on osteo-
clasts and their precursors, engages RANKL (RANK ligand)
expressed on BMSCs and osteoblasts, thereby triggering
osteoclast differentiation and resorptive activity. It remains con-
troversial whether MM cells themselves express RANKL or not;
nonetheless, their presence potentiates osteoclast activity by
(1) upregulation of RANKL expression in BMSCs (Roux et al.,
2002); (2) decreased levels of osteoprotegerin (OPG), which
functions as decoy against RANKL; (3) upregulation of multiple
pro-osteoclastogenic cytokines (e.g., IL-6, IL-1α, IL-1β, IL-11,
MIP-1α, M-CSF, TNF-α, PTHrP, and VEGF, which are either
produced by MM cells or by host BM cells [e.g., BMSCs] due to
paracrine/juxtacrine stimulation by MM cells [Ashcroft et al.,
2003; Han et al., 2001]); and/or (4) increased levels, in subsets
of MM patients with extensive bone lesions, of receptor for
hyaluronan-mediated motility (RHAMM) (Maxwell et al., 2004)
or of Dickoppf-1 (DKK-1) (Tian et al., 2003), an inhibitor of Wnt
signaling, which inhibits differentiation of osteoblast precursor
cells, conceivably contributing to uncoupling of bone formation
from excessive resorption in MM.
The BM microenvironment constitutes a sanctuary for MM
cells: their adhesion to extracellular matrix, BMSCs, and other
cells of the BM milieu activates in MM cells a pleiotropic cas-
cade of proliferative/antiapoptotic signaling pathways, including
PI-3K/Akt/mTOR/p70S6K, IKK-α/NF-κB, Ras/Raf/MAPK, and
JAK/STAT3; as well as downstream effectors, including cyto-
plasmic sequestration of proapoptotic Forkhead transcription
factors; upregulation of D-type cyclins, caspase inhibitors, anti-
apoptotic Bcl-2 family members; and increased activity of the
proteasome, telomerase and HIF-1α (Hideshima et al., 2001a;
Mitsiades et al., 2002b, 2004a). These molecular events are
triggered either directly, via cell adhesion molecule-mediated
interactions of MM cells with BMSCs, osteoblasts, other BM cel-
lular compartments, or the extracellular matrix (Landowski et
al., 2003), or indirectly, via cytokines/growth factors released by
BMSCs and/or MM cells and engaging their respective recep-
tors on the MM cell surface. The expanding list of such
paracrine/autocrine proliferative/survival factors includes inter-
leukin-6 (IL-6), insulin-like growth factors (IGFs), IL-1α, IL-1β,
HGF, VEGF, SDF-1, TNF-α, or Notch family members (Chauhan
et al., 1996; Hideshima et al., 2004; Mitsiades et al., 2002a,
2004a; Nefedova et al., 2004). Many of these factors also
induce pleiotropic indirect effects on MM cells by stimulating
osteoclastogenesis (IL-6, IL-1, VEGF), modulating adhesion
molecule profiles on MM cells and BMSCs (TNF-α), or promot-
ing MM cell homing to the BM milieu (e.g., SDF-1) (Hideshima
et al., 2004). Recent data highlight that IGFs and their receptor
IGF-1R (CD221) play a more prominent role in MM pathophysi-
ology than previously appreciated (Mitsiades et al., 2004a).
Levels of IGFs are high in serum and even higher locally in the
BM milieu due to paracrine release by osteoblasts and BMSCs
(Mitsiades et al., 2004a), and IGFs confer more pronounced
and sustained activation of proliferative/antiapoptotic signaling
(e.g., PI-3K/Akt, IKK/NF-κB) than other BM-derived cytokines,
e.g., IL-6 (Mitsiades et al., 2002a). IGF-1R signaling therefore
emerges as a key regulator of MM cell biological behavior: it
activates multiple proliferative/antiapoptotic cascades (includ-
ing proteasome and telomerase activities), attenuates anti-MM
activity of several antitumor drugs (including dexamethasone,
cytotoxic chemotherapy, and proteasome inhibitors), primes
MM cell responsiveness to other cytokines (e.g., IL-6), and
stimulates production of angiogenic cytokines (Mitsiades et al.,
2004a). Importantly, even though PCL cells can proliferate and
survive independently of many BM-derived cytokines (e.g., IL-
6), they maintain significant responsiveness to selective inhibi-
tion of IGF-1R signaling (Mitsiades et al., 2004a).
The composite clinical impact of these bidirectional MM
cell-BM microenvironment interactions is detrimental not only
as a direct result of osteolytic lesions, but also as indirect
repercussion of the resistance that the BM milieu confers to
MM cells against conventional chemotherapeutics or glucocor-
ticoids, even in the absence of genetic lesions that would con-
fer constitutive resistance (Hideshima et al., 2001a, Mitsiades
et al., 2004a). This may explain, at least in part, the lack of
curative outcome with conventional therapies, raising intriguing
hypotheses about putative interpatient variation in the intrinsic
biological behavior of BM microenvironment per se, and also
underscores the significance of MM studies in preclinical mod-
els which recapitulate the complex circuitry of tumor-BM inter-
actions, in order to define novel therapies to specifically target
their entire spectrum. This is critical since MM cell-driven oste-
olysis and BM microenvironment-determined drug resistance
are highly multifactorial, with substantial potential for redun-
dancy and ensuing resistance to treatments targeting only indi-
vidual mediators of these processes.
The intricate tumor-microenvironmental intreractions and
their role in in vivo drug resistance are not restricted to MM, but
are increasingly recognized as critical features of other neo-
plasias (Allinen et al., 2004).The molecular basis for distinct dif-
ferences in the tropism and clinical phenotype of these
interactions in MM versus other diseases remains to be deter-
mined. It is possible that those genetic lesions, which contribute
to establishment of MGUS/MM, not only confer enhanced prolif-
erative capacity and/or increased resistance to apoptosis, but
also modulate the ability of MM cells to interact with their BM
stromal milieu: MM cells with t(14;16) translocations overex-
press the transcription factor c-maf, which transactivates the
cyclin D2 promoter, enhancing myeloma cell proliferation, but
also drives β7-integrin expression and enhanced MM cell adhe-
sion to BMSCs (Hurt et al., 2004). Hyperdiploidy is proposed to
render MM cells uniquely dependent on the BM environment,
which possibly drives their cyclin D1 overexpression despite
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absence of Ig translocations (Hideshima et al., 2004). These
cases exemplify putative associations between specific genetic
lesions and particular pathways mediating MM-microenviron-
mental interactions.
Recent advances in the therapeutic management of
myeloma
For decades, MM treatment was based on cytotoxic chemother-
apy, e.g., conventional dose melphalan-prednisone as front-line
therapy for elderly patients and high-dose chemotherapy (HDT)
with hematopoietic (autologous or allogeneic) stem cell sup-
port, aiming at higher rate and magnitude of responses in
patients with favorable prognostic features. Recent data indi-
cate modest, but consistent, benefits of single HDT with autolo-
gous stem cell support over standard-dose chemotherapy
(Child et al., 2003), and, mainly in patients with suboptimal
response to 1st HDT, of tandem double HDT over single HDT
(Attal et al., 2003). An important role for bisphosphonates in
management of MM bone complications is also established
(Berenson et al., 2002). Yet a radical recent shift in MM thera-
peutics was the application of agents e.g., thalidomide (Thal),
immunomodulatory Thal derivatives (IMiDs), and proteasome
inhibitors (Richardson et al., 2002, 2003; Singhal et al., 1999),
which have different molecular targets than chemotherapeutics.
Thal was proposed for MM treatment based on its antian-
giogenic properties (D’Amato et al., 1994) and successfully
applied by Singhal et al., leading to objective clinical responses
(>50% decrease in monoclonal Ig levels) in ?1/3 of MM
patients with relapsed refractory MM (Singhal et al., 1999), with
higher response rates when combined with other agents, e.g.,
dexamethasone (Rajkumar et al., 2002; Weber et al., 2003).
The immunomodulatory Thal derivative (IMiD) CC-5013
(Revlimid, lenalidomide) can be clinically active even in MM
patients resistant to Thal, is not teratogenic in in vivo preclinical
models, and exhibits manageable adverse event profile, devoid
of the potential of Thal for peripheral neuropathy, somnolence,
and constipation (Richardson et al., 2002). The diverse pro-
posed mechanisms of anti-MM action of Thal and CC-5013
include not only antiangiogenic effects, but also direct antiprolif-
erative and proapoptotic effects on MM cells, through inhibition
of NF-κB transcriptional activity and activation of death recep-
tor/caspase-8-mediated death signaling (Mitsiades et al.,
2002d); modulation of MM-BMSC adhesive interactions and
abrogation of secretion of prosurvival cytokines (Hideshima et
al., 2000); and stimulation of NK cell number and cytotoxic
activity against MM cells (Davies et al., 2001).
MM is also a prototypic disease model for antitumor activity
of proteasome inhibitors, such as the boronic dipeptide borte-
zomib (PS-341). The proteasome functions in both normal and
neoplastic cells to degrade ubiquitinated intracellular proteins
destined for recycling of their building blocks (Hershko and
Ciechanover, 1998). However, MM cells appear to be highly
dependent on 20S proteasome function, since inhibition of chy-
motryptic activity of its β5 subunit by bortezomib triggers (1)
concomitant activation of caspase-8 (via c-myc- and AP-1-
mediated upregulation of Fas/FasL), caspase-9, and endoplas-
mic reticulum stress response, via inhibition of IRE1 activity
(Lee et al., 2003; Mitsiades et al., 2002c), and (2) suppression
of intracellular antiapoptotic pathways, e.g., intracellular accu-
mulation of IκB and suppression NF-κB-dependent antiapoptot-
ic proteins (e.g., FLIP, cIAP-2, and other caspase inhibitors)
(Mitsiades et al., 2002c). Consequently, bortezomib is active
even against drug-resistant MM cells in vitro and in vivo
(Hideshima et al., 2001b) and offers objective clinical responses
in approximately 1/3 of heavily pretreated MM patients with
relapsed refractory disease (Richardson et al., 2003), as well as
superior clinical outcome, compared to high-dose dexametha-
sone, in relapsed MM (P.G. Richardson et al., 2004, Proc. Am.
Soc. Clin. Oncol., abstract).
While these new therapies target, at least in part, the
responsiveness of MM cells to BM-determined antiapoptotic
stimuli, their administration is not considered curative: not all
patients are responsive, and drug resistance eventually devel-
ops even in responders, conceivably due to interpatient hetero-
geneity and intrapatient evolution in the genetic makeup and
microenvironmental interactions of MM cells. Two distinct but
mutually complementing ongoing approaches to address this
challenge are the development of new classes of antitumor
agents and the combinatorial use of existing and novel anti-MM
drugs.
Many novel therapies developed for MM (Figure 1) either
directly deprive MM cells of their ability to respond to prolifera-
tive and antiapoptotic microenvironmental cues, and/or target
the sources of these stimuli, i.e., MM-stromal adhesion, bone
resorption, or neoangiogenesis. The former goal can be
achieved through agents which selectively inhibit (1) cell sur-
face receptors or downstream effectors in signaling cascades
mediating MM cell proliferation/drug resistance in the BM milieu
(e.g., IGF-1R, FGFR-3, IKK-α, farnesyltransferase, mTOR)
(Bolick et al., 2003; Chesi et al., 2002; Hideshima et al., 2004;
F O C U S
Figure 1. Schematic overview of emerging therapeutic targets in MM
Many emerging therapies for MM target the ability of MM cells to respond
to proliferative/antiapoptotic microenvironmental cues. The levels of
actions of these therapies are diverse, and include cell surface growth fac-
tors receptors (e.g IGF-1R), their downstream signaling effectors (e.g., Akt,
IKK-α), cell adhesion molecules, posttranslational regulators of protein
expression (e.g., proteasome) or 3-dimensional conformation and function
(e.g., hsp90), regulators of transcriptional responses (e.g., HDACs) or
replicative potential (e.g., hTERT), and inhibitors of bone resorption (e.g.,
RANK-Fc decoys or OPG constructs).
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Mitsiades et al., 2004a; Shi et al., 2002), (2) pathways regulat-
ing MM cell adhesion (e.g., c-met) (Hov et al., 2004), (3) molec-
ular chaperones, such as hsp90, which simultaneously
regulates the 3-dimensional conformation and function of multi-
ple proliferative/antiapoptotic kinases in MM cells (Mitsiades et
al., 2002a), (4) histone deacetylases (HDACs), which regulate
transcription of oncogenic/antiapoptotic genes differentially
expressed in MM cells (Mitsiades et al., 2003c, 2004b), or (5)
telomerase (Shammas et al., 2004), which regulates long-term
replicative potential of MM cells and is functionally modulated
by BM cytokine signaling (Mitsiades et al., 2004a). Therapies
with direct microenvironmental focus may target adhesion mole-
cules mediating MM-stromal interactions (e.g., α4-integrin)
(Mori et al., 2004), counteract bone resorption, e.g., RANK-Fc
decoys or OPG constructs (Body et al., 2003; Sordillo and
Pearse, 2003; Vanderkerken et al., 2003), or aim at disrupting
tumor-associated endothelial cells (e.g., VEGF receptor signal-
ing inhibitors) (Lin et al., 2002). The immunomodulatory proper-
ties of thalidomide also rekindled the interest of the MM field in
immune-based therapies, e.g., DNA or peptide vaccines
(Heslop et al., 2003) or adoptive immunotherapy with T cells
(Kwak et al., 2004). Following its successful clinical use in acute
promyelocytic leukemia, arsenic trioxide appears to have bio-
logical activity against MM, with diverse proposed mechanisms
of action (Hussein et al., 2004; McCafferty-Grad et al., 2003).
Many of these therapies (e.g., inhibitors of IGF-1R kinase,
hsp90, or HDACs) (Mitsiades et al., 2002a, 2003c, 2004a) trig-
ger pleiotropic molecular sequelae via simultaneous targeting
of multiple pathways and/or versatile biological functions of their
individual molecular targets. The latter are not necessarily over-
expressed or mutationally activated in MM cells (compared to
normal cells), highlighting the importance of functional screen-
ings for identification of novel therapeutic targets.
For the design of more effective anti-MM combination regi-
mens, a consistent effort is made to rationally partner treat-
ments that neutralize potential mechanisms of resistance to
each other, simultaneously target multiple distinct critical path-
ways for tumor cell survival, and/or affect different functional lev-
els within the same pathway. Using molecular profiling and
functional studies of drug-treated MM cells in vitro and in vivo to
define regimens which satisfy these criteria, several such com-
binations have translated into clinical applications, including
combinations of thalidomide or its derivatives with dexametha-
sone or the proteasome inhibitor bortezomib, or combinations
of bortezomib with cytotoxic chemotherapy or hsp90 inhibitors
(Hideshima et al., 2000; Mitsiades et al., 2002a, 2002c, 2002d,
2003d). The synergy of bortezomib with chemotherapeutics
(e.g., alkylating agents or antracyclines) is confirmed both in
vitro and in vivo, even in MM cases resistant to both therapies
administered separately (Mitsiades et al., 2003d; Orlowski,
2004), and involves concomitant abrogation of distinct molecu-
lar determinants of MM cell chemoresistance, including NF-κB
transcriptional activity, inhibitors of apoptosis (IAPs), and genes
involved in DNA damage repair (Mitsiades et al., 2003d).
Both the development of novel classes of anti-MM agents
and their rational incorporation into combination regimens have
been bolstered by drug testing in preclinical models recapitulat-
ing the intricate MM-BM milieu interaction, either in vitro (MM-
BMSC coculture assays) or in vivo (SCID-NOD models of
diffuse MM bone lesions [Mitsiades et al., 2003b, 2004a] or
SCID-hu model of syngeneic MM-BMSC in vivo interaction
[Urashima et al., 1997;Yaccoby et al., 1998]).These models are
particularly important for assessment of in vivo drug efficacy,
since subcutaneous xenograft models, commonly used in other
disease settings, do not recapitulate the osteotropism of MM
and the multifactorial protection it receives (even in advanced
disease) by the BM milieu (Mitsiades et al., 2004a). The difficul-
ty in assessing tumor response in models of diffuse lesions is
addressed by use of MM cells transduced with luciferase and/or
green fluorescent protein constructs, allowing for sensitive and
noninvasive real-time quantification of tumor burden with whole-
body fluorescence and/or bioluminescence imaging, respec-
tively (Mitsiades et al., 2003b, 2004a).
Contributions of MM research to conceptual progress in
cancer research: Future challenges
The notion of MM as a rare disease with little broader relevance
for cancer research has been replaced by its emergence as a
prototypic disease model for development of key concepts in
cancer pathophysiology and therapeutics. The study of tumor-
stromal interactions and their role in in vivo drug resistance, the
development of proteasome inhibition, thalidomide and its
derivatives, or IGF-1R kinase inhibition to specifically overcome
microenvironmentally determined drug resistance, and the
streamlined drug testing in in vivo models with clinically relevant
distribution of diffuse tumor lesions are some of the critical con-
tributions by MM research. The lack of curative treatments for
MM has also transformed it into a critical testing ground for an
expanding armamentarium of new therapeutics. The genetic
complexity and heterogeneity of MM cells and/or BM microenvi-
ronment severely limit the likelihood of curative outcome with
any single class of agents. A critical challenge will be to interdig-
itate the expanding knowledge on molecular profiling, novel in
vivo models, and developmental therapeutics with clinical prac-
tice and offer clinically applicable combination therapies match-
ing the molecular features of the disease in individual patients,
in order to effectively counteract drug resistance and/or prevent
disease- or treatment-related complications (Mitsiades et al.,
2003a). If these challenges are successfully met, the MM field
will also provide a valuable blueprint for overcoming these criti-
cal hurdles in other disease-specific oncological fields.
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